Regardless of this marginal clinical utility, the ultimate goal of measuring sACE2 activity depends on the ability to target medically the activation of ACE2-Angiotensin (1–7) pathway, rather than serving as a non-invasive tool to predict the occurrence of adverse LV remodeling following myocardial infarction. Here, ACE2 is linked to myocardial infarction.